预约演示
更新于：2026-05-18
Cephalexin
头孢氨苄
更新于：2026-05-18
概要
基本信息
简介头孢氨苄，也被称为KEFLEX®，是一种半合成的头孢菌素类抗生素药物，通过抑制PBPs发挥作用。它于1971年首次由Pragma Pharmaceuticals LLC在美国获得口服用途的批准。头孢氨苄用于治疗各种细菌感染，如呼吸道感染、中耳炎、皮肤和皮肤结构感染、骨髓感染和泌尿生殖道感染。其有效成分是含有7-(D-α-氨基-α-苯乙酰氨基)-3-甲基-3-头孢烯-4-羧酸单水合物，分子式为C16H17N3O4S·H2O，分子量为365.41。KEFLEX®胶囊适用于口服。 |
药物类型 小分子化药 |
别名 Ammonia benzyl cephalosporin、Cafalexin、Cefaiexin + [25] |
靶点 |
作用方式 抑制剂 |
作用机制 PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H19N3O5S |
InChIKeyAVGYWQBCYZHHPN-CYJZLJNKSA-N |
CAS号23325-78-2 |
关联
123
项与 头孢氨苄 相关的临床试验NCT07300670
The Effect of Losartan on Cephalexin
The goal of this clinical trial is to investigate the effects of the blood pressure-lowering drug losartan on the blood levels and urinary excretion of the antibiotic cephalexin during simultaneous and staggered ingestion in healthy volunteers. The main questions it aims to answer are:
1. Does losartan affect cephalexin levels and excretion when ingested at the same time?
2. Does a three-hour interval between ingestion of losartan and cephalexin eliminate a possible effect?
Researchers will compare the effects of losartan ingested at the same time, losartan ingested three hours prior, and no losartan ingested on oral cephalexin in each participant to see whether an interaction exists and could be avoided.
Participants will visit the research laboratory on three days during which they will ingest single doses of losartan at the same time with, three hours prior to, and not at all prior to ingesting single doses of cephalexin.
1. Does losartan affect cephalexin levels and excretion when ingested at the same time?
2. Does a three-hour interval between ingestion of losartan and cephalexin eliminate a possible effect?
Researchers will compare the effects of losartan ingested at the same time, losartan ingested three hours prior, and no losartan ingested on oral cephalexin in each participant to see whether an interaction exists and could be avoided.
Participants will visit the research laboratory on three days during which they will ingest single doses of losartan at the same time with, three hours prior to, and not at all prior to ingesting single doses of cephalexin.
开始日期2026-03-04 |
申办/合作机构 |
NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.
开始日期2025-05-05 |
申办/合作机构 |
NCT04401553
First Tier Versus Second Tier Antibiotics for Surgical Site Infections Following Hysterectomy In the Patients With a Beta-Lactam Allergy: A Prospective, Randomized, Single-Blinded Clinical Trial
Postoperative surgical site infection (SSI) is associated with unnecessary use of heath care resources including prolonged hospitalization and increased hospital readmission. Perioperative antibiotic prophylaxis is one of the most important strategies for prevention of SSI. If there is a beta-lactam allergy, second tier antibiotics (vancomycin and clindamycin) are recommended alternatives to first- and second-generation cephalosporins because of fears of possible allergy.
This prospective, randomized, and single-blinded clinical trial is designed to examine causality between second tier antibiotics use and surgical site infections in the subjects with a documented unverified penicillin allergy. Unverified beta-lactam allergy could be associated with antimicrobial treatment failure with second tires antibiotics during postoperative period.
This prospective, randomized, and single-blinded clinical trial is designed to examine causality between second tier antibiotics use and surgical site infections in the subjects with a documented unverified penicillin allergy. Unverified beta-lactam allergy could be associated with antimicrobial treatment failure with second tires antibiotics during postoperative period.
开始日期2024-08-16 |
100 项与 头孢氨苄 相关的临床结果
登录后查看更多信息
100 项与 头孢氨苄 相关的转化医学
登录后查看更多信息
100 项与 头孢氨苄 相关的专利（医药）
登录后查看更多信息
4,487
项与 头孢氨苄 相关的文献（医药）2026-06-01·Current drug discovery technologies
Analyze the Sombor Index of Molecular Graphs Representing Antibiotic Drugs using the ℳ Polynomial
Article
作者: Senbagamalar, Jaishankar ; Ramani, Mangalam Sivalingam ; Remella, Venkata Shivakumar
Introduction::
Today's world is grappling with numerous infectious diseases and pandemics caused by bacteria, viruses, fungi, or parasites, which are affecting people at an alarming rate. Molecular topology, a field that significantly influences drug design and discovery, involves the algebraic description of chemical compounds, enabling their distinctive and straightforward characterization.
Materials and Methods::
Among various applications, the topological indices can be generated from ℳ-polynomial. ℳ-polynomial is a generating function that has been proposed to unify the computation of diverse topological indices. It contains degree-based topological data of molecular graphs and facilitates the derivation of multiple degree-based topological indices in an efficient manner. The ℳ-polynomial can be used to derive different degree-based topological indices by using different transformations. Computational efficiency offers a common method for calculating several topological indices. QSAR/QSPR Models are employed to examine molecular properties and biological activity in drug design.
Results::
The Sombor index, a molecular descriptor, was studied in the context of several antibacterial medications, including Amoxicillin, Ampicillin, Tetracycline, Doxycycline, Cefalexin, and Ciprofloxacin. These drugs are commonly used to treat conditions such as bladder infections, rickettsial infections, pneumonia, bronchitis, and other respiratory tract infections.
Discussion::
In this study, the edge partition technique is employed to derive the ℳ-polynomial for selected antibacterial drug molecules. The graphical representation of the respective molecular structures is calculated and discussed based on the derived ℳ-polynomial.
Conclusion::
To construct the ℳ -polynomial and derive the Sombor index for antibiotic drugs, then correlate them with the physicochemical properties of these drugs to analyze the regression models for the best fit.
2026-06-01·AQUATIC TOXICOLOGY
The integration of transcriptomics, intestinal microbiota and physiology reveals the toxic mechanism of cephalexin in rainbow trout
Article
作者: Gu, Wei ; Wang, Junwei ; Fan, Peng ; Liu, Zhicen ; Gao, Hangfei ; Fan, Ze ; Zhao, Chenyang ; Huang, Tianqing ; Xu, Gefeng ; Gao, Lei ; Wang, Xinyang
Cephalexin (CFX) is a widely used antibiotic that has formed a certain background concentration in the environment. This widespread residue poses a potential threat to the health of aquatic organisms. However, the toxicological mechanisms of CFX in aquatic organisms have not been fully investigated. This study reveals the toxicological mechanisms of rainbow trout under exposure to different concentrations of CFX. The experiment found that tissue damage and inflammatory responses in the gills and intestines of rainbow trout were positively correlated with the concentration of CFX. Meanwhile, CFX exposure induced extensive oxidative stress responses. Transcriptomic analysis showed that CFX exposure significantly upregulated the activation of linoleic acid metabolism, α-linolenic acid metabolism, and steroid biosynthesis pathways in the liver. The metabolism of xenobiotics by cytochrome P450 in the gills was upregulated, and pathways such as steroid hormone biosynthesis and tryptophan metabolism were also affected. Microbiota community composition analysis indicated that Pseudomonadota was the dominant phylum, with a significant increase in Firmicutes and a decrease in Bacteroidota. Overall, this study systematically analyzed the effects of CFX on rainbow trout from multiple levels. It not only elucidated the tissue damage and oxidative stress in different organs but also comprehensively assessed the molecular regulatory mechanisms. These findings provide a scientific basis for understanding the impact of antibiotic pollution on aquaculture.
2026-05-01·European Journal of Obstetrics & Gynecology and Reproductive Biology
Postoperative oral cephalexin and metronidazole effectiveness in preventing complications in obese pregnant women undergoing cesarean delivery: A systematic review and meta-analysis
Review
作者: Oliveira, Juliana Almeida ; Queiroz, Laura Fonseca ; Lemos, Maria Julia ; Pinheiro Mello, Pedro Lucas ; Servidoni, Ana Clara Pimenta ; Dias, Yasmin Jardim Meirelle ; Aljunaid, Linda ; Sciorilli, João Vitor
This meta-analysis aimed to evaluate the effectiveness of adding postoperative oral cephalexin and metronidazole to standard preoperative prophylaxis in preventing surgical site infections (SSI) among obese women undergoing cesarean delivery. We systematically searched PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for randomized controlled trials. Studies involving obese women undergoing cesarean delivery with the intervention of postoperative oral cephalexin plus metronidazole were included. Data were analyzed using a random-effects model to pool risk ratios (RRs) with 95% confidence intervals (CIs). Three randomized controlled trials, encompassing 1144 patients, were included. The pooled analysis revealed that postoperative oral cephalexin and metronidazole significantly reduced the incidence of cellulitis (RR 0.50; 95% CI 0.28-0.89; p = 0.01). However, no statistically significant differences were found for other outcomes, including wound separation (RR 0.68; 95% CI 0.40-1.14), fever (RR 0.49; 95% CI 0.08-3.01), composite SSI (RR 0.55; 95% CI 0.29-1.05), endometritis (RR 0.49; 95% CI 0.13-1.94), or wound seroma (RR 0.9; 95% CI 0.51-1.57). Sensitivity analysis indicated the significance for cellulitis was sensitive to individual studies. In conclusion, the addition of postoperative oral cephalexin and metronidazole reduces cellulitis incidence in obese women following cesarean section. While a broader impact on other surgical site infections was not observed, this targeted benefit for cellulitis suggests a potential role as an adjunct to current prophylaxis. Further robust research is needed to validate these findings and refine preventive strategies.
163
项与 头孢氨苄 相关的新闻（医药）2026-05-13
Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期
https://academic.oup.com/jac/issue
50th Anniversary Collection（50周年纪念合集）
Review（综述）
1
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review
人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述
Anisia Talianu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470
Reviews（综述）
2
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America
耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现
Lillian Rose Giarratana and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340
3
Azithromycin resistance in non-typhoidal Salmonella: a review
非伤寒沙门氏菌对阿奇霉素的耐药性：综述
Zhe Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341
4
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications
抗生素药效动力学：从最低抑菌浓度到高级指标及其应用
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374
5
Progress in the study of drug resistance mechanism of Bacillus cereus
蜡样芽孢杆菌耐药机制研究进展
Yuhang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399
6
The curious constraints on clofazimine
氯法齐明的奇特限制
Maple Goh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430
7
Antiplasmid systems: a novel strategy to combat antibiotic resistance
抗质粒系统：对抗抗生素耐药性的新策略
Mohd Asim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472
Systematic Review（系统综述）
8
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes
欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述
Priya Shastri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407
9
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method
用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述
Najla Alabdulkarim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446
Virtual Roundtable（虚拟圆桌会议）
10
Procalcitonin in the management of lower respiratory tract infection and sepsis
降钙素原在下呼吸道感染和败血症治疗中的应用
Ramy H Elshaboury and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298
Original Research（论著）
11
Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients
来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估
Chrisoula Tahtsidou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427
12
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435
13
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study
评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究
Nicolas Grégoire and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381
14
Real-life use of isavuconazole in Spanish children and adolescents
西班牙儿童和青少年中艾沙康唑的实际使用情况
Natalia Mendoza-Palomar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394
15
No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis
基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号
Slobodan M Jankovic and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395
16
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较
Nirjan Bhattarai and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396
17
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究
Beibei Liang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398
18
Differences in prescription for impetigo and cellulitis across years in three European countries
三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异
Thomas Bettuzzi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400
19
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit
重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度
Karolina Liljedahl Prytz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401
20
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较
Jelmer Raaijmakers and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402
21
Identification of antimicrobial resistance genes in Escherichia coli through network diffusion
通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因
Anis Mansouri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404
22
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease
依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估
Sanjay Singh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405
23
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406
24
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction
解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系
Maria Montaner and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408
25
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge
不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战
Ana C Almeida-Santos and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409
26
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果
Romain Palich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410
27
HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda
乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联
Anne Kapaata and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411
28
Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States
美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况
Sarah C J Jorgensen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412
29
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies
奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究
Saskia E Mudde and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413
30
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023)
后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023）
Mekki F Bensaci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414
31
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions
慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联
Gabriel P E Silveira and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416
32
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis
博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析
Biao Tang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418
33
Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation)
基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释）
Yinzheng Zhong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419
34
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights
印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察
Shristi Verma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420
35
Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations
减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421
36
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性
Reham Mostafa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422
37
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing
危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药
Sonya Tang Girdwood and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423
38
Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients
达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量
W Töpfer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424
39
Notable transmitted HIV drug resistance among people who inject drugs in Pakistan
巴基斯坦注射毒品人群中显著传播的HIV耐药性
Stephanie Melnychuk and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425
40
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性
Ahmed Ashrin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426
41
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model
中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究
Panagiota-Christina Georgiou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431
42
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗
Clayton F Hausberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432
43
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
阿普拉霉素及其组合对脓肿分枝杆菌的增强活性
Yanqin Huang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433
44
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene
印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制
Dipika Shaw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434
45
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者
Delphine Girlich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436
46
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli
blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征
Pengpeng Min and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437
47
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients
血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性
Thornthun Ueaphongsukkit and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439
48
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性
Marion Dutkiewicz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440
49
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效
Kirby Patterson-Fahy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441
50
Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate
利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性
Ruonan Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442
51
Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？
Manon Launay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443
52
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析
Ernesto Martínez-Buitrago and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444
53
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
基于模型的含固定剂量多替拉韦方案减量策略比较
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445
54
Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE)
住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究）
Pjotr P Temme and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447
55
Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究
Jose Valdes Ledesma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448
56
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study
采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究
Sacha Kuil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451
57
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高
Josefine Ahlstrand and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452
58
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定
Cathia Soulie and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454
59
Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications
延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455
60
β-Lactam dosing in critically ill children: predictors for target non-attainment
危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素
Stef Schouwenburg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457
61
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis
实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况
Barbara Alexander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461
62
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes
携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462
63
Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input
预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联
María M Montero and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464
64
A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations
全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局
Efi Mantzourani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466
65
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus
提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试
Henriëtte M Meliefste and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468
Research Letters（研究快报）
66
Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany
德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731
Henrike Krüger-Haker and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336
67
Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report
厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告
Monica Melchio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347
68
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加
Jose F Camargo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348
69
Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring
达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用
Ambra Barco and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365
70
Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report
血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告
Kohei Hasegawa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373
71
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390
72
Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy
产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播
Gloria D’Achille and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397
73
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据
Tommaso Clemente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415
74
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker
猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况
Gi Yong Lee and Soo-Jin Yang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428
75
Importance of reviewing the package insert from gradient strip manufacturers
梯度扩散法药敏纸片生产商说明书审阅的重要性
Mandy Wootton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429
76
One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene
一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成
Christopher J Harmer and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450
77
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿
Cristina Gómez-Ayerbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456
78
In vitro activity of gepotidacin against Chlamydia trachomatis
吉皮达星对沙眼衣原体的体外活性
Arabella Touati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460
Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期
https://academic.oup.com/jac/issue
Viewpoints（观点）
1
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？
Aleece MacPhail and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471
2
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies
靶向治疗时代急性白血病抗真菌预防的重新定义
Marcio Nucci and Johan Maertens
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010
Reviews（综述）
3
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae
替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展
Meilin Wu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504
4
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations
两性霉素B脂质体与肾脏安全性：证据回顾及临床考量
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473
5
Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略
Keiji Okinaka and Joshua T Schiffer
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489
Systematic Reviews（系统综述）
6
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis
吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析
Taha Ibrahim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469
7
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review
产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述
Bruna Abdul Ahad Saad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476
8
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae
决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析
Sambit Kumar Dwibedy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503
9
Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review
促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490
Original Research（论著）
10
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究
M B D Nielsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487
11
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients
体外膜肺氧合模式对危重患者伏立康唑暴露的影响
Xinrui Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501
12
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案
Dustin Huynh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449
13
Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis
铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析
Karolina Anna Mielko-Niziałek and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453
14
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性
Carlo Tascini and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467
15
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands
荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况
Patrick D J Sturm and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475
16
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant
Acinetobacter baumannii
模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用
Xiaonan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477
17
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case
加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478
18
The effect of intrauterine exposure to aminoglycosides on neonatal hearing
宫内暴露于氨基糖苷类抗生素对新生儿听力的影响
Daniel Leshin-Carmel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483
19
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies
头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略
Jiaju Zhuo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495
20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果
Xinying Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502
21
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis
肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况
Pascal Chavanet and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474
22
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi
用于检测广泛耐药伤寒沙门菌的快速分子诊断技术
Emma L Sweeney and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481
23
Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22
性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析
Deepshikha Batheja and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002
24
Real-world evaluation of isavuconazole in children with cancer
伊沙康唑在儿童癌症患者中的现实应用评估
Janine Nijhuis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485
25
Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study
加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究
Joseph Elikem Efui Acolatse and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003
26
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性
Guan-Jhou Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488
27
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates
吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性
Michelle Jayne Cole and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001
28
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析
Ye-Lei Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006
29
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用
Andres Mazariegos Herrera and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014
30
evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology
运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架
Ryan A Hamilton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438
31
First characterization of insertions in the HIV-1 integrase-coding region from people with HIV
首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析
Nhat Quang Tu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491
32
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法
Caitlin N Daniels and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493
33
Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats
新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究
Hitesh A Kadu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008
34
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents
欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究
Marika A de Hoop-Sommen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463
35
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究
R C Wilson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484
36
Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy
性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响
Maria Vittoria Cossu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024
37
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学
Julius J Schmidt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496
38
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制
Yoshinori Yamano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004
39
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD
基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响
Yao Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500
40
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia
评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498
Research Letters（研究快讯）
41
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告
J Kimmerlin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459
42
Proposal for the nomenclature of tmexCD-toprJ-like gene clusters
关于tmexCD-toprJ样基因簇命名的建议
Chengzhen Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482
43
IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae
IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合
Yan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018
Letter to the Editor（致编辑的信）
44
Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论
Gwénola Marais and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465
45
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply
意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027
ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家）
46
Acknowledgement of Referees
鸣谢审稿专家
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417
CORRECTION（更正）
47
Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492
Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期
https://academic.oup.com/jac/issue
REVIEW（综述）
1
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations
缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架
Josep M Llibre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052
2
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation
成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍
Daniel B Chastain and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055
3
Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future
细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案
Daisuke Fukuda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054
4
Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions
应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向
Robiul Islam and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064
SYSTEMATIC REVIEW（系统综述）
5
Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析
Stamatis Karakonstantis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037
Original Research（论著）
6
The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting
三级门诊常规剂量口服环丙沙星对患者QT间期的影响
Weber Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020
7
Bictegravir concentrations in breastmilk of healthy, lactating women without HIV
未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度
L C van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022
8
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究
Anastasia Saade and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021
9
Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究
Tomoyuki Ishigo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012
10
Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure
HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用
Jolieke A T van Osch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033
11
Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies
体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响
Jie Gao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032
12
Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease
用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究
Seef Abdalla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019
13
Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24
2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总
Robyn Thorington and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007
14
Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool
使用新型决策支持工具改进围手术期预防性抗生素处方
Mark Mcintyre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015
15
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study
针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究
Ángel Rodríguez-Villodres and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034
16
Impact of eravacycline on fibrinogen
依拉环素对纤维蛋白原的影响
Emily Stevenson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030
17
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients
原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究
Milo Gatti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009
18
Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates
从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性
Natsuki Yamanaka and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017
19
In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究
Si-Ho Kim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031
20
LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state
LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效
Xing Xia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036
21
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV
HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用
Giuseppe Lapadula and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045
22
Pharmacokinetics of colistin in adult critically ill patients in South Africa
南非成人危重症患者中多黏菌素的药代动力学研究
Veshni Pillay-Fuentes Lorente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011
23
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)
2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测
Su Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016
24
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study
短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究
Beatriz Borjabad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040
25
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials
美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析
Priscilla Y Hsue and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005
26
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection
采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究
Thomas Lin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039
27
Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries
撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式
Abubaker Ibrahim Elbur and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497
28
Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study
老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究
Arnaud De Clercq and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048
29
Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations
基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案
Wenyan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499
30
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study
快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究
Salvatore Rotundo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056
31
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK
与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析
Laura Ciaccio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049
32
Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study
英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038
33
Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究
Win Min Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053
34
A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025
基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析
Connor Frey and Parham Elmi
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060
35
Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs
体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据
Huifang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063
36
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes
在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果
Laura Pezzati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035
37
A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa
用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型
Yali Fan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061
38
Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery
微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果
Quentin Saint-Genis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071
39
Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers
伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型
Hui Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065
40
Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study
利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068
41
Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort
当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据
Katja Wallander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067
42
Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China
治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究
Litai Qin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073
RESEARCH LETTER（研究快讯）
43
Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy
嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎
Yan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041
44
The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib
糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击”
Bianca Monti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028
45
Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis
Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子
Francesca Romana Massacci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046
46
HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir
HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库
Rémi Rouget and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050
47
An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data
一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告
Pierangelo Chinello and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013
48
Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales
碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法
Hippolyte De Swardt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066
49
Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence
头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051
LETTERS TO THE EDITOR（致编辑的信）
50
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Chris Kenyon
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025
51
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply
来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权
Jose F Camargo and Anthony D Anderson
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043
52
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply
意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026
53
Comment on: Artificial intelligence for improving decision-making in bacterial infection management
述评：人工智能在细菌感染管理决策中的优化作用
Daniele Roberto Giacobbe
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078
CORRECTION（更正）
54
Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study
更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494
55
Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057
Journal of Antimicrobial Chemotherapy Volume 81, Issue 4抗菌化疗杂志81卷 4期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
GARROD LECTURE（加罗德讲座）
1
Garrod lecture: achieving the UNGA AMR mortality reduction goals
加罗德讲座：实现联合国大会抗菌药物耐药性死亡率降低目标
Ramanan Laxminarayan
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag082, https://doi.org/10.1093/jac/dkag082
REVIEW（综述）
2
25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat?
侵袭性曲霉病血液病患者25年死亡率改善情况：这种改善能否持续，还是正受到威胁？
Johan A Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag077, https://doi.org/10.1093/jac/dkag077
3
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit
针对锥虫病的从高质量潜在客户和药物开发候选者出发的战略发现路线图。第二部分：从分子到确证活性分子
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag110, https://doi.org/10.1093/jac/dkag110
VIRTUAL ROUNDTABLE（虚拟圆桌会议）
4
Diagnosis and risk factors for invasive mould disease—a round table discussion on directing antifungal therapy according to the available evidence
侵袭性霉菌病的诊断与危险因素——根据现有证据指导抗真菌治疗的圆桌讨论
Ana Alastruey-Izqueirdo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag062, https://doi.org/10.1093/jac/dkag062
EDITORIALS, MESSAGES FROM THE OUTGOING AND INCOMING EDITORS-IN-CHIEF（社论、离任与就任主编寄语）
5
Message from the incoming Editor-in-Chief of JAC
《抗菌化疗杂志》就任主编寄语
Monica A Slavin
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf479, https://doi.org/10.1093/jac/dkaf479
6
Message from the outgoing Editor-in-Chief
离任主编寄语
J Peter Donnelly
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf480, https://doi.org/10.1093/jac/dkaf480
REVIEW（综述）
7
Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems
用于药代动力学和药效学研究的实验性生物膜模型：连接体外、离体和体内系统
Stephanie Supparitsch and Markus Zeitlinger
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag091, https://doi.org/10.1093/jac/dkag091
8
Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics
感染性坏死性胰腺炎的抗菌治疗：微生物学、抗菌药物耐药性及药代动力学
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag092, https://doi.org/10.1093/jac/dkag092
9
Continuous linezolid infusion: the new way to dose, the old risks to fear
持续输注利奈唑胺：新的给药方式，仍需警惕旧有风险
Daniel Muñoz-Pichuante and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag100, https://doi.org/10.1093/jac/dkag100
10
Alignment of national standard treatment guidelines with WHO AWaRe recommendations for adult primary care infectious diseases: implications for antimicrobial stewardship
将国家标准治疗指南与世卫组织（WHO）针对成人初级保健传染病的“慎用、监测、备用”（AWaRe）推荐意见相统一：对抗菌药物管理的影响
Huda Arooj and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag099, https://doi.org/10.1093/jac/dkag099
SYSTEMATIC REVIEW（系统综述）
11
Healthcare providers’ experiences in caring for MDRO carriers with a focus on the moral dimensions of care: a systematic review
医疗服务提供者护理多重耐药菌（MDRO）携带者的经历——聚焦护理中的道德维度：一项系统综述
Carlijn Damsté and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag059, https://doi.org/10.1093/jac/dkag059
12
Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review
奥利他万星药代动力学/药效学目标的外推用以指导治疗药物监测：一项系统综述
Giammarco Baiardi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag117, https://doi.org/10.1093/jac/dkag117
ORIGINAL RESEARCH（论著）
13
Beyond plasma: defining the translation value of epithelial lining fluid exposure profiles for the treatment of pneumonia
超越血浆：明确上皮衬里液暴露谱对肺炎治疗的转化价值
Yakun Fu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf458, https://doi.org/10.1093/jac/dkaf458
14
Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study
负荷剂量β-内酰胺类药物治疗非重症监护病房患者产KPC肺炎克雷伯菌血流感染的疗效影响：一项现实研究
Luisa Frallonardo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag087, https://doi.org/10.1093/jac/dkag087
15
Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro
雷扎芬净在体外对真菌生物膜表现出抗生物膜特性
Hafsa Abduljalil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag058, https://doi.org/10.1093/jac/dkag058
16
Vancomycin resistance predicts increased mortality in patients with Enterococcus faecium bloodstream infections: a six-year experience at a large tertiary care Italian hospital
万古霉素耐药性可预测屎肠球菌血流感染患者死亡率增加：意大利一家大型三级医院六年来的经验
Lucia Graziani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag069, https://doi.org/10.1093/jac/dkag069
17
Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database
氟喹诺酮类药物与惊恐发作风险：基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库中个体病例安全报告的系统综述和比例失衡分析
Keeirah Hiertika Raguram and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag083, https://doi.org/10.1093/jac/dkag083
18
Cefuroxime concentrations in facial artery musculomucosal flap, buccal submucosa, subcutaneous tissue, and plasma following bolus or continuous infusion in patients undergoing oral cancer resection: a randomized clinical microdialysis study
在接受口腔癌切除术的患者中，采用随机临床微透析研究，探究头孢呋辛在面动脉肌黏膜瓣、颊黏膜下层、皮下组织和血浆中的浓度（团注或持续输注后）
Johanne Ravn Hansen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag085, https://doi.org/10.1093/jac/dkag085
19
Infection point of care tests bridge the experience gap of antibiotic STOP decisions: clinicians versus students
感染即时检测可弥补抗生素停药决策方面的经验差距：临床医生与学生对比
Archit Singhal and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf486, https://doi.org/10.1093/jac/dkaf486
20
Functional analysis of a novel macrolide–lincosamide resistance gene erm(57) in Cutibacterium avidum
痤疮丙酸杆菌中一种新型大环内酯 - 林可酰胺类耐药基因erm(57)的功能分析
Juri Koizumi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag029, https://doi.org/10.1093/jac/dkag029
21
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial
莱索托和坦桑尼亚病毒血症儿童及青少年中的HIV耐药性：GIVE MOVE试验的嵌套分析
Christof Manuel Schönenberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag070, https://doi.org/10.1093/jac/dkag070
22
Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients
在儿科重症监护患者回顾性队列中识别和评估儿科头孢吡肟诱导的神经毒性
Kathryn Pavia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag075, https://doi.org/10.1093/jac/dkag075
23
Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database
整合酶抑制剂和非核苷类逆转录酶抑制剂相关不良事件的优先级排序：基于FAERS数据库数据的比例失衡分析
Gao-yang Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag074, https://doi.org/10.1093/jac/dkag074
24
Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020
自2020年以来西班牙多队列分析中，儿童、青少年及青年时期感染HIV者的临床及免疫病毒学状态
Laura Tarancon-Diez and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag079, https://doi.org/10.1093/jac/dkag079
25
Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study
接受体外膜肺氧合治疗的危重成年患者美罗培南的群体药代动力学——一项ASAP ECMO研究
Mohd H Abdul–Aziz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag090, https://doi.org/10.1093/jac/dkag090
26
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing
2022年至2024年意大利流行HIV-1亚型间传播耐药性的评估：通过下一代测序技术进行的精细分析
Daniele Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag084, https://doi.org/10.1093/jac/dkag084
27
Characterization of efflux pump channel of florfenicol for resistance-enhancing variant RE-CmeABC in Campylobacter
耐药增强型变异体RE-CmeABC中氟苯尼考外排泵通道在弯曲菌中的特性研究
Hong Yao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag047, https://doi.org/10.1093/jac/dkag047
28
Genomic characterization of colistin heteroresistance in Acinetobacter baumannii: Evidence for lpxD deletion and collateral sensitivity
鲍曼不动杆菌中黏菌素异质性耐药的基因组特征：lpxD缺失及附带敏感性的证据
Banu Sancak and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag076, https://doi.org/10.1093/jac/dkag076
29
Sustaining stewardship: longitudinal evaluation of an integrated antimicrobial programme in the ICU
持续管理：重症监护室（ICU）综合抗菌药物管理项目的纵向评估
Ashmitha Thomas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag086, https://doi.org/10.1093/jac/dkag086
30
Global dissemination of optrA-mediated linezolid resistance in enterococci
利奈唑胺耐药性基因optrA介导的肠球菌在全球的传播
Jia Qi Beh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag089, https://doi.org/10.1093/jac/dkag089
31
Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing
利用肠外头孢菌素敏感性试验预测大肠杆菌血培养分离株对口服头孢菌素的敏感性
Tho H Pham and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag093, https://doi.org/10.1093/jac/dkag093
32
The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models
在小鼠大腿和肺部感染模型中多粘菌素B对鲍曼不动杆菌的药效动力学研究
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag097, https://doi.org/10.1093/jac/dkag097
33
Genomic insights into the tmexCD-toprJ: plasmid-mediated evolution, dissemination and diversity in bacterial populations
关于tmexCD-toprJ的基因组见解：质粒介导的细菌群体进化、传播与多样性
Lilan Wan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag107, https://doi.org/10.1093/jac/dkag107
34
Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study
初治患者基线耐药突变与多替拉韦病毒学应答：一项多中心下一代测序（NGS）研究
Alexy Inciarte and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag080, https://doi.org/10.1093/jac/dkag080
35
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study
非洲非B型HIV-1毒株中与多替拉韦（DTG）基因型耐药相关的新型整合酶突变：DTG耐药研究
Nuri Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag088, https://doi.org/10.1093/jac/dkag088
36
Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model
体外宫颈阴道HIV预防模型的药理学评估
Lindsey B Collins and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag103, https://doi.org/10.1093/jac/dkag103
37
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions
NOSO-502药效学指数的幅度：病原体清除、耐药性出现和人体剂量预测
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag106, https://doi.org/10.1093/jac/dkag106
38
Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales?
替莫西林：治疗第三代头孢菌素耐药肠杆菌目引起的骨关节感染的一种替代疗法？
Louise Piquart and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag105, https://doi.org/10.1093/jac/dkag105
39
Metallo-β-lactamase–producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors
产金属β-内酰胺酶的肠杆菌科细菌：含氰化物的外排泵抑制剂作为潜在的双活性抑制剂
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag122, https://doi.org/10.1093/jac/dkag122
40
Outer membrane vesicles transmit blaNDM-5 and package metallo-β-lactamases to promote antibiotic resistance in Escherichia coli
外膜囊泡传递blaNDM-5并包装金属β-内酰胺酶以促进大肠杆菌的抗生素耐药性
Ting-Yin Lu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag123, https://doi.org/10.1093/jac/dkag123
41
Characterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin
一株鸡源ST412-K57多粘菌素耐药高毒力肺炎克雷伯菌的特征分析
Qiu Xu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag114, https://doi.org/10.1093/jac/dkag114
42
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study
奥罗芬明与唑类抗真菌药联合使用：2期挽救治疗研究结果
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag118, https://doi.org/10.1093/jac/dkag118
RESEARCH LETTER（研究快讯）
43
Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion
母体病毒得到抑制，婴儿仍发生HIV传播：一例断奶后血清转阳病例
Shadia Nakalema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag072, https://doi.org/10.1093/jac/dkag072
44
Urinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy
危重患者中尿抗原阴性军团菌肺炎：系统分子检测在优化抗菌治疗中的价值
Livia Foglia Manzillo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag101, https://doi.org/10.1093/jac/dkag101
45
Contribution of SHV-1 overexpression to carbapenem resistance in a Klebsiella pneumoniae clinical isolate
SHV-1过表达对某株肺炎克雷伯菌临床分离株碳青霉烯类抗生素耐药性的影响
Céline Plainvert and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag108, https://doi.org/10.1093/jac/dkag108
LETTER TO THE EDITOR（致编辑的信）
46
Comment on: Possible increased risk of Epstein–Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
评论：接受莱特莫韦治疗的造血细胞移植受者中，EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加
Jan Styczynski
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag042, https://doi.org/10.1093/jac/dkag042
47
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis users in Milan, Italy
评论：意大利米兰地区使用多西环素暴露后预防措施人群中针对细菌性性传播感染的抗菌药物使用情况
Luca Bortolani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag023, https://doi.org/10.1093/jac/dkag023
48
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes—right to reply
使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净药物治疗监测的回顾性分析——答复权
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag095, https://doi.org/10.1093/jac/dkag095
49
Comment on: Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched-cohort study
评论：替莫西林与其他静脉注射β-内酰胺类抗生素治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究
Shanshan Ru and Yingzhe Zhang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag096, https://doi.org/10.1093/jac/dkag096
50
Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
评论：长效糖肽类抗生素：对于最需要它们的患者，获取的障碍是什么，如何克服？
Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag102, https://doi.org/10.1093/jac/dkag102
51
Comment on ‘Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes’
评论：“对使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净的药理学治疗监测的回顾性分析”
Julien Massol and Frédéric Baud
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag094, https://doi.org/10.1093/jac/dkag094
52
Comment on: ‘Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp’
对“除塞拉蒂亚属（Serratia spp）外肠杆菌目所致心内膜炎的流行病学和治疗”的评论
Gianpiero Tebano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag098, https://doi.org/10.1093/jac/dkag098
53
‘Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–2021-right-to-reply’
“比较肺炎球菌疫苗的血清型覆盖率——PCV21（V116，一种新型21价结合肺炎球菌疫苗）与加拿大成人患者中导致侵袭性肺炎球菌疾病的其8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学：SAVE研究，2018 - 2021年——回应”
John J Schellenberg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag126, https://doi.org/10.1093/jac/dkag126
54
Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus
评论：奥罗芬明与伏立康唑对烟曲霉的体外拮抗作用
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag119, https://doi.org/10.1093/jac/dkag119
55
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.: right-to-reply
除塞氏杆菌属外肠杆菌科细菌所致心内膜炎的流行病学和治疗：回应
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag121, https://doi.org/10.1093/jac/dkag121
Journal of Antimicrobial Chemotherapy Volume 81, Issue 5抗菌化疗杂志81卷 5期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
REVIEW（综述）
1
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage
针对动基体病的高质量先导化合物及药物开发候选物的战略发现路线图。第一部分：背景介绍
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag109, https://doi.org/10.1093/jac/dkag109
REVIEW（综述）
2
Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury
多粘菌素相关急性肾损伤的病理生理学、危险因素及临床治疗
Simiao Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag132, https://doi.org/10.1093/jac/dkag132
SYSTEMATIC REVIEW（系统综述）
3
Definitions and rates of treatment failure in females with uncomplicated urinary tract infection: a systematic literature review
女性单纯性尿路感染治疗失败的定义及发生率：一项系统文献综述
Meghan E Luck and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag112, https://doi.org/10.1093/jac/dkag112
4
Therapeutic drug monitoring and the role of pharmacokinetics/pharmacodynamics in optimizing beta-lactam antibiotic dosing for deep-seated infections: a systematic review
在针对深部感染的β-内酰胺类抗生素优化给药方案中治疗药物监测以及药代动力学/药效学的作用：一项系统综述
Cassandra Vale and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag142, https://doi.org/10.1093/jac/dkag142
ORIGINAL RESEARCH（论著）
5
Optimizing cloxacillin prophylaxis in hip and knee arthroplasty based on population pharmacokinetics of unbound plasma concentrations
基于游离血浆浓度群体药代动力学优化髋关节和膝关节置换术中的氯唑西林预防用药方案
Gustaf Beijer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag116, https://doi.org/10.1093/jac/dkag116
6
The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat
大鼠静脉注射[14C]奥洛罗芬后的组织分布及药代动力学研究
Derek Law and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag120, https://doi.org/10.1093/jac/dkag120
7
Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli in South and South-East Asia
世界卫生组织三轮车项目（Tricycle）协同的弗莱明基金南亚和东南亚地区外部质量评估（EQASIA EQA）计划在检测南亚和东南亚地区产超广谱β-内酰胺酶（ESBL）、AmpC酶和碳青霉烯酶的大肠埃希菌方面的见解
Hiba Al-Mir and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag129, https://doi.org/10.1093/jac/dkag129
8
The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV
HIV感染者肌内注射长效卡博特韦和利匹韦林后的血浆及细胞内暴露情况
Micol Ferrara and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag113, https://doi.org/10.1093/jac/dkag113
9
In vitro synergistic activity of minocycline and biapenem against cefiderocol-resistant New Delhi metallo-β-lactamase-producing Enterobacterales
米诺环素与比阿培南在体外对产新德里金属β-内酰胺酶且对头孢地尔耐药的肠杆菌科细菌的协同作用
Takashi Okanda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag128, https://doi.org/10.1093/jac/dkag128
10
Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort
产超广谱β-内酰胺酶大肠埃希菌菌血症的死亡风险：基于PROBAC队列的综合分析
Paula Olivares-Navarro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag130, https://doi.org/10.1093/jac/dkag130
11
Molecular mechanism of envZ regulating β-lactam antibiotic resistance and virulence in Escherichia coli
EnvZ调控大肠埃希菌β-内酰胺类抗生素耐药性及毒力的分子机制
Kun Yang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag104, https://doi.org/10.1093/jac/dkag104
12
In vitro activity of amoxicillin combined with oral cephalosporins against endocarditis-associated E. faecalis clinical isolates
阿莫西林联合口服头孢菌素针对心内膜炎相关粪肠球菌临床分离株的体外活性
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag127, https://doi.org/10.1093/jac/dkag127
13
Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis
全基因组关联研究构建预测模型并揭示大环内酯类耐药百日咳鲍特菌的新耐药特征
Jialiang Chen and Guowei Liang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag131, https://doi.org/10.1093/jac/dkag131
14
Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity
减量持续静脉输注头孢吡肟方案的实际应用验证：药效学目标达成情况、疗效及神经毒性
Kieffer Korvin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag138, https://doi.org/10.1093/jac/dkag138
15
Cross-species and cross-border spread of aph(3′)-ia-mediated neomycin resistance in Escherichia coli from animals: a genomic perspective
从基因组角度研究动物源大肠杆菌中aph(3′)-ia介导的新霉素耐药性的跨物种和跨国传播
Mattia Pirolo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag143, https://doi.org/10.1093/jac/dkag143
16
Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance
美国烟曲霉临床分离株集合中cyp51A变异体的流行情况及其对三唑类抗真菌药物耐药性作用的比较分析
Luisa Fernanda Gómez Londoño and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag124, https://doi.org/10.1093/jac/dkag124
17
In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance
达托霉素联合头孢洛林对高水平氨基糖苷类耐药及非耐药粪肠球菌所致实验性心内膜炎的体内外疗效研究
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag136, https://doi.org/10.1093/jac/dkag136
18
Pharmacokinetics of a three-dose regimen of intramuscular benzathine penicillin G in pregnant women with syphilis
三剂苄星青霉素G肌内注射方案在妊娠期梅毒患者中的药代动力学研究
Eshetie Melese Birru and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag145, https://doi.org/10.1093/jac/dkag145
19
Cefiderocol resistance mediated by mutation of the miniconductance mechanosensitive channel MscM in Klebsiella oxytoca
由产气克雷伯菌中微小电导机械敏感通道MscM发生突变所介导的头孢地尔耐药性
Pia Turowski and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag147, https://doi.org/10.1093/jac/dkag147
20
The veterinary clinic backyard lawn used for relief walks of hospitalized dogs is a hotspot for OXA-type carbapenemases in multiple Enterobacterales
兽医诊所后院供住院犬只散步的草坪是多种肠杆菌科细菌中OXA型碳青霉烯酶的传播热点区域
Yvonne Spahr and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag144, https://doi.org/10.1093/jac/dkag144
21
Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective
头孢唑林在减肥手术患者中的药代动力学：术前视角
Alexandra Porlier and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag150, https://doi.org/10.1093/jac/dkag150
RESEARCH LETTERS（研究快讯）
22
Plasmid-encoded FRI-10 carbapenemase harboured by non-Enterobacter species isolated from a wastewater sample in Tokyo, Japan
从日本东京废水样本中分离出的非肠杆菌科物种携带质粒编码的FRI-10碳青霉烯酶
Kou Murakami and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag133, https://doi.org/10.1093/jac/dkag133
23
Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants
头孢吡肟/恩美唑巴坦与美罗培南、哌拉西林、哌拉西林/他唑巴坦、西他沙星和磷霉素针对携带blaKPC等位基因变体的肺炎克雷伯菌的协同作用
Alice Crema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag141, https://doi.org/10.1093/jac/dkag141
24
MRSA and carbapenem-resistant Acinetobacter baumannii on the fall: successful infection prevention and control in Chilean ICUs
耐甲氧西林金黄色葡萄球菌和耐碳青霉烯类鲍曼不动杆菌数量下降：智利重症监护病房感染预防与控制的成功案例
Patricio Ross and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag146, https://doi.org/10.1093/jac/dkag146
LETTER TO THE EDITOR（致编辑的信）
25
Comment on: Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic–pharmacodynamic modelling in adults and infants
评论：基于模型的评估VRC07-523LS在婴儿中的给药剂量——基于成人和婴儿群体药代动力学-药效学模型
Wanhua Qiu
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag139, https://doi.org/10.1093/jac/dkag139
26
Comment on: Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21
评论：比较含21种血清型的肺炎球菌疫苗PCV21（V116）（一种新型21价结合肺炎球菌疫苗）的血清型覆盖范围，以及2018 - 2021年SAVE研究中导致加拿大成年患者侵袭性肺炎球菌疾病的8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学情况
Gokul Raj Pullagura and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag125, https://doi.org/10.1093/jac/dkag125
27
Comment on: Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
评论：肉鸡源和人临床来源肠球菌分离株中NarAB的不同种群结构和基因组背景
Alex Wong
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag134, https://doi.org/10.1093/jac/dkag134
28
Distinct population structure and genomic context of narAB between broiler and human clinical Enterococcus isolates—authors’ response
肉鸡源和人临床来源肠球菌分离株中narAB的不同种群结构和基因组背景——作者回复
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag135, https://doi.org/10.1093/jac/dkag135
2026-05-12
核心结论
翰森制药是中国传统药企向创新驱动型制药企业成功转型的标杆典范。 公司自1995年成立以来，经历了从仿制药起步到创新药主导的战略升级，已在抗肿瘤、中枢神经系统、代谢及自身免疫等重大疾病领域建立了显著的竞争优势。2025年，公司实现总收入150.28亿元人民币，同比增长22.6%，净利润55.55亿元，同比增长27.1%，创新药收入占比提升至82.2%，标志着公司已基本完成从仿到创的历史性转变。公司估值处于行业中等水平（2025年PE约34倍），考虑到其强劲的盈利增长、丰富的研发管线（40余个候选创新药、70余项临床试验）以及持续兑现的国际化BD交易（累计超90亿美元），我们认为公司具备长期投资价值。1. 公司概况与发展历程1.1 公司基本信息
翰森制药集团有限公司（Hansoh Pharmaceutical Group Company Limited，股票代码：03692.HK）于2019年6月14日在香港联交所主板挂牌上市，是中国领先的创新驱动型制药企业。公司总部位于上海市浦东新区，拥有9347名员工，其中研发人员超过1900名12^。公司注册于开曼群岛，通过旗下豪森药业、常州恒邦药业、翰森生物医药等子公司开展业务，重点关注抗肿瘤、抗感染、中枢神经系统（CNS）、代谢及自身免疫等重大疾病治疗领域12^。截至2025年5月，公司总股本约60.64亿股，控股股东Stellar Infinity Company Ltd.持股比例为64.41%，实际控制人为公司创始人钟慧娟7^。
公司的业务定位经历了深刻转型。从成立之初的"仿创结合、仿制打基础、创新求突破"战略，到如今以创新药为核心驱动力，翰森制药用近三十年时间完成了从仿制药企业向综合性创新制药集团的跃迁。截至2025年底，公司已有7款创新药在中国产生销售收入，11项适应症纳入国家医保目录，所有已获批创新药适应症均已进入医保体系，充分体现了公司产品的临床价值和市场竞争力6^。1.2 发展历程与关键里程碑
翰森制药的发展史是一部中国制药企业创新转型的缩影。1995年7月，公司前身江苏豪森药业由恒瑞医药创始人孙飘扬与香港投资人共同创办，孙飘扬当时担任连云港制药厂厂长，其妻钟慧娟辞去中学化学教师的工作，加入豪森药业并承担管理重任7^8^。1997年，公司首款核心产品、抗生素药物"美丰"上市，当年实现收入3000万元；同年，连云港制药厂完成股份制改造更名为恒瑞医药，由此形成了中国医药界最知名的"夫妻档"——孙飘扬执掌恒瑞医药，钟慧娟执掌翰森制药，各自打造了一家千亿市值的上市公司9^10^。
2002年是公司创新征程的起点，公司开始研制1.1类创新药，并于同年改制为股份制公司。2014年，公司的迈灵达（吗啉硝唑氯化钠注射液）获批上市，成为全球40年来首个硝基咪唑类抗厌氧菌创新药，标志着公司自主创新能力的重大突破7^。2019年6月，翰森制药在港交所成功上市，募资用于研发管线推进和产能扩张。上市后，公司加速创新转型，2020年推出中国首个原研三代EGFR-TKI阿美乐（阿美替尼），2022年创新药收入占比首次超过50%，2024年该比例进一步升至77.3%，2025年达到82.2%12^21^。
2023年以来，公司在国际化BD交易方面取得了令人瞩目的成就，先后与GSK、默沙东、Regeneron、罗氏等全球顶级制药企业达成多项重磅授权合作，累计交易总额超过90亿美元21^。这些合作不仅验证了公司研发实力获得国际认可，也为公司打开了全新的增长空间。2025年，公司创始人钟慧娟凭借1410亿元财富首次问鼎中国女首富，这一标志性事件也从侧面印证了翰森制药在资本市场的卓越表现8^。1.3 股权结构与公司治理
翰森制药的股权结构相对集中，有利于战略决策的高效执行。控股股东Stellar Infinity Company Ltd.持有公司64.41%的股份，实际控制人钟慧娟通过复杂的持股架构实现对公司的控制12^。钟慧娟与女儿孙远合计持有公司股权比例超过60%，形成了家族控股的稳定治理结构7^。这种股权集中度在港股生物医药板块中较为常见，有助于公司在长期创新战略上保持定力和连贯性。
公司治理层面，钟慧娟担任创始人、董事会主席、首席执行官兼执行董事，全面负责公司战略规划和运营管理。吕爱锋博士（48岁）担任执行董事，孙远女士（38岁）担任执行董事，体现了管理层的新老交替和家族传承。公司还拥有一支专业化的职业经理人团队，包括首席财务官胡敏先生、首席技术官姜山博士、首席科学官李志鸿博士、首席商务官孙维勇博士和首席医学官张晓青博士12^。2025年，钟慧娟的薪酬为1382万元，在港股上市药企中处于合理水平。2. 财务状况与经营业绩2.1 营收与利润分析
翰森制药近年来的财务表现充分体现了创新驱动增长的战略成效。2025年，公司实现总收入150.28亿元人民币，同比增长22.6%，年度溢利55.55亿元，同比增长27.1%，每股基本盈利0.93元21^22^23^。这一业绩增速在港股生物医药板块中名列前茅，尤其是在行业整体面临医保谈判降价和竞争加剧的背景下，更显珍贵。
从历史数据来看，公司在2020年至2025年间实现了稳健增长，仅在2022年因疫情和仿制药集采影响出现小幅下滑（营收93.82亿元，同比-5.6%），但迅速在2023年恢复正增长（营收101.04亿元，同比+7.7%），此后增速持续加快。2024年公司营收122.61亿元，同比增长21.3%，净利润43.72亿元，同比大幅增长33.4%1^。2025年的业绩进一步提速，营收和利润增速均保持在20%以上，显示出公司创新转型已进入收获期。
图1：翰森制药2020-2025年营业收入与净利润趋势（数据来源：公司年报，ifind）
值得注意的是，公司的盈利质量持续优化。2025年经营活动净现金流入达到67.38亿元，年末现金及银行存款高达315.49亿元23^。充裕的现金储备为后续研发投入、全球拓展及创新转化提供了坚实保障，也使公司在行业下行周期中具备更强的抗风险能力。2.2 创新药收入驱动增长
创新药收入的快速放量是公司业绩增长的核心驱动力。2025年，公司创新药与合作产品销售收入达到123.54亿元，同比增长30.4%，占总收入比重提升至82.2%21^23^。回顾这一转变历程：2020年创新药收入仅约9.5亿元，占比11%；2022年达到50亿元，占比53.4%；2023年增至68.65亿元，占比67.9%；2024年达到94.77亿元，占比77.3%12^。短短五年间，创新药收入增长了约12倍，占比提升了超过70个百分点，这一转型速度和深度在国内传统药企中极为罕见。
图2：翰森制药2020-2025年创新药收入占比与研发投入趋势（数据来源：公司年报，ifind）
从收入结构来看，抗肿瘤领域是公司的核心增长极。2025年抗肿瘤领域实现收入99.74亿元，占总收入的66.4%，同比增长22.8%5^6^。中枢神经系统领域收入13.10亿元（占8.7%），抗感染领域收入15.86亿元（占10.6%），代谢及其他疾病领域收入21.58亿元（占14.3%）21^。四大板块协同发力，形成了多点突破的多元化增长格局。2.3 盈利能力与费用管控
翰森制药的盈利能力在行业中处于领先水平。2025年，公司毛利率维持在91%左右，净利率提升至37%，ROE（净资产收益率）达到15.7%21^。高毛利率主要得益于创新药产品的定价优势和公司在成本控制方面的精细化管理。随着创新药收入占比的持续提升，公司的整体盈利能力有望继续保持强劲。
图5：翰森制药2020-2025年核心财务指标趋势（数据来源：公司年报，ifind）
在费用管控方面，公司呈现"研发增、销售降"的良性趋势。2025年研发开支为33.58亿元，同比增长24.3%，占收入比例达22.3%23^。2019年至今，公司累计研发开支已超过100亿元15^16^。与此同时，销售费用率从2020年的36%逐步下降至2025年的约28%，反映出公司从仿制药向创新药转型过程中，营销策略的优化调整——创新药凭借较强的临床竞争力，无需过度依赖高费用的营销手段12^。管理费用率维持在约8%的合理水平，财务费用因公司现金充裕而保持在极低水平。2.4 资产负债与现金流状况
翰森制药的资产负债表极为稳健。截至2025年底，公司总资产约为440亿元人民币，总负债约41亿元，资产负债率仅为9.3%32^。公司几乎无有息负债，财务杠杆极低，这在高研发的生物医药行业中是显著优势。流动资产中，现金及银行存款315.49亿元23^，交易性金融资产约29亿元，为公司提供了充足的流动性保障。
现金流方面，2025年经营活动现金流净流入67.38亿元，投资活动现金流净流出约19亿元（主要用于研发投入和产能建设），筹资活动现金流净流出约84亿元（主要为分红和股票回购）。公司2025年拟每股派息20港仙23^，按当前股价计算股息率约为1.2%，兼顾了股东回报和长期发展投入。3. 核心产品与市场表现3.1 抗肿瘤领域：阿美乐与豪森昕福双轮驱动
抗肿瘤领域是翰森制药最核心的收入来源，2025年实现收入99.74亿元，同比增长22.8%5^6^。该领域由两款重磅创新药阿美乐（甲磺酸阿美替尼片）和豪森昕福（甲磺酸氟马替尼片）构成双轮驱动格局。
阿美乐是中国首个原研三代EGFR-TKI创新药，于2020年3月获批上市，用于治疗非小细胞肺癌（NSCLC）。截至2026年1月，阿美乐已累计获批5项适应症，覆盖晚期一线、二线、术后辅助、局部晚期放化疗后维持治疗及靶化联合等核心治疗场景，成为国内获批适应症最广、治疗领域最广的中国原研三代EGFR-TKI6^。2025年，阿美乐新增3项适应症获批上市，其中2项已纳入国家医保目录，并获得了8部国家级诊疗指南的I级/首选推荐21^。临床研究数据显示，阿美乐联合化疗一线治疗可降低53%的疾病进展或死亡风险，中位无进展生存时间（mPFS）达28.9个月6^。在商业化推广方面，阿美乐2025年6月获得英国MHRA批准上市，成为首个实现海外上市的中国原研EGFR-TKI；2026年2月再获欧盟EC批准；2025年12月与印度Glenmark达成超过10亿美元的海外授权合作6^。市场预测阿美乐的峰值销售有望达到80亿元人民币12^。
豪森昕福是中国首个原研新型二代BCR-ABL抑制剂，于2019年11月获批上市，用于治疗慢性髓性白血病（CML）。2025年，氟马替尼持续巩固其在CML治疗领域的市场地位，累计有4项临床研究入选欧洲血液学协会（EHA）和美国血液学会（ASH）年会6^。该产品已被《中国国家卫生血病诊疗指南》和CSCO《恶性血液病诊疗指南》推荐为CML一线治疗药物，并继续保留在国家医保目录内6^。
图3：翰森制药2025年各业务板块收入构成与创新药占比（数据来源：公司年报，ifind）3.2 中枢神经系统领域：昕越引领罕见病布局
中枢神经系统（CNS）领域2025年实现收入13.10亿元，占总收入的8.7%6^。该领域的核心产品是昕越（伊奈利珠单抗注射液），这是中国首个且唯一的抗CD19单抗，用于治疗视神经脊髓炎谱系疾病（NMOSD）。2025年，昕越新增两项罕见病适应症获批，包括IgG4相关性疾病和全身型重症肌无力（gMG）6^，进一步巩固了公司在罕见病和自身免疫领域的领先地位。此外，公司在CNS领域还拥有阿美宁（阿戈美拉汀片）、艾兰宁（帕利哌酮缓释片）、欧兰宁（奥氮平片/口崩片/口溶膜）等成熟产品，形成了覆盖抑郁、失眠、精神分裂症等患者规模较大适应症的产品矩阵12^。3.3 抗感染领域：恒沐确立慢乙肝治疗地位
抗感染领域2025年实现收入15.86亿元，占总收入的10.6%21^。该领域的核心产品是恒沐（艾米替诺福韦片），这是中国首个原研口服抗乙肝病毒药物。凭借明确的临床优势，恒沐已累计获得16项权威指南推荐，成为慢乙肝治疗的优选方案之一。另一款创新药迈灵达（吗啉硝唑氯化钠注射液）是全球40年来首个硝基咪唑类抗厌氧菌创新药，于2014年获批上市7^。此外，公司引进的第四代抗真菌药物艾瑞芬净（Ibrexafungerp）也已在国内获批上市，针对外阴阴道念珠菌病适应症，侵袭性念珠菌病适应症处于III期临床阶段12^。3.4 代谢及其他领域：GLP-1赛道潜力释放
代谢及其他疾病领域2025年实现收入21.58亿元，占总收入的14.3%21^，是增长最快的板块之一。该领域拥有两款核心产品：孚来美（聚乙二醇洛塞那肽注射液）是国产首款原研GLP-1RA周制剂，用于治疗2型糖尿病；圣罗莱（培莫沙肽注射液）是全球唯一获批上市的EPO模拟肽，用于治疗肾性贫血，被连续纳入多项中国慢性肾脏病管理专家共识6^。
更重要的是，公司在GLP-1赛道的在研产品奥莱泊肽（HS-20094，GLP-1/GIP双受体激动剂）展现出巨大潜力。2026年3月，HS-20094在中国超重或肥胖成人受试者中开展的首个III期临床研究（HS-20094-301）达成主要终点，治疗48周体重较基线平均降幅最高达19.3%，实现≥5%体重降幅的受试者比例最高达97.2%6^。尤其值得关注的是，该产品在胃肠道耐受性方面表现优异，恶心发生率平均不到10%，呕吐发生率平均不到5%，与已发表的GLP-1相关双激动剂类药物III期试验数据相比，胃肠道不良事件发生率及治疗停药率更低6^。HS-20094已于2025年6月以最高20.1亿美元的交易总额授权给Regeneron（不含中国内地、香港及澳门）12^，充分体现了其国际商业价值。4. 研发管线与创新能力4.1 研发投入与技术平台
翰森制药始终坚持高强度研发投入，为创新转型提供坚实支撑。2025年公司研发开支为33.58亿元，同比增长24.3%，占收入比例达22.3%23^。2019年上市至今，公司累计研发开支已超过100亿元15^16^。公司组建了由1900余名海内外专业研发人员组成的团队，拥有国家级技术中心、博士后科研工作站、国家重点实验室等多个国家级研发称号15^。
公司建立了9大创新技术平台，涵盖PROTAC、siRNA、融合蛋白、ADC（抗体偶联药物）、双抗、单抗、纳米制剂和PEG修饰长效药物等前沿领域12^。这些平台的系统布局使公司具备了从靶点发现到临床开发的全链条研发能力，也为后续持续产出创新产品奠定了技术基础。截至2025年底，公司在中国提交专利申请40件，海外专利申请128件，全球范围内获授权专利80项，知识产权壁垒持续加固6^。4.2 研发管线全景
截至2025年底，翰森制药拥有超过40个处于临床不同阶段的创新药项目，正在开展的临床试验超过70项6^。仅在2025年报告期内，公司就新增了8个首次进入临床的候选药，新增7项III期关键注册临床试验6^23^。
图7：翰森制药研发管线阶段分布与已上市创新药产品时间线（数据来源：公司年报、公开资料整理）
在ADC赛道，公司的布局尤为突出。除了已授权给GSK的HS-20093（B7-H3 ADC）和HS-20089（B7-H4 ADC）外，公司还在推进CDH17 ADC（HS-20110）、CDH6 ADC等早期管线。HS-20093正在中国开展用于小细胞肺癌、骨肉瘤适应症的III期临床研究，已累计获得中国NMPA授予的3项突破性治疗药物认定、美国FDA授予的2项突破性疗法认定及1项孤儿药资格认定、欧洲EMA授予的优先药物认定及1项孤儿药资格认定6^。2025年10月，公司将HS-20110授权给罗氏，交易总额超过15.3亿美元21^。
在肿瘤靶向治疗领域，公司在阿美替尼基础上构建了完整的EGFR/MET闭环战略。高选择性MET-TKI药物Dalmelitinib（HS-10241）联合阿美替尼治疗EGFR-TKI耐药后MET扩增NSCLC的Phase Ib期临床数据显示，中位无进展生存期（mPFS）达7.4个月，中位总生存期（mOS）高达25.4个月4^。此外，公司从百奥泰引进的EGFR/cMet双特异性抗体HS-20117/PM1080，与自身ADC平台结合开发的双抗ADC药物HS-20122已进入临床阶段4^。
在自身免疫与肾病领域，公司在研的HS-10374（TYK2选择性变构抑制剂）用于中重度斑块状银屑病已进入III期临床，有望成为国产首个获批的TYK2药物12^。从荃信生物引进的靶向IL-23p19单抗HS-20137同样处于III期临床阶段。在IgA肾病领域，公司自主研发的补体因子B抑制剂HS-10542正处于早期临床阶段4^。
在CNS领域，公司在研管线针对抑郁、失眠、精神分裂症等大适应症，包括GABA调节剂HS-10353、O3/O2/5-HT2A受体调节剂HS-10380等12^。4.3 BD合作：引进与输出双轨并行
翰森制药采用"引进与输出"双轨并行的策略，通过外部合作不断充实高潜创新管线。在引进（License-in）方面，2019年至今公司累计达成十余项license-in交易15^，包括从百奥泰引进EGFR/cMet双抗、从荃信生物引进IL-23p19单抗、从路鹏制药引进BTK抑制剂LP-168等。这些合作使公司能够快速获取处于临床中后期的成熟创新产品，缩短了研发周期。
在输出（License-out）方面，公司2023年以来取得了突破性进展，成为中国创新药企国际化授权交易最活跃的企业之一。
图6：翰森制药2023-2025年主要对外授权（BD）交易汇总（数据来源：公司公告、公开资料整理）时间合作方产品靶点/类型交易总额（亿美元）2023.12GSKHS-20093B7-H3 ADC15.0 6^2023.12GSKHS-20089B7-H4 ADC15.0 6^2024.12MSDHS-10535口服GLP-1小分子20.1 18^2025.06RegeneronHS-20094GLP-1/GIP双受体激动剂20.1 12^2025.10RocheHS-20110CDH17 ADC15.3 21^2025.12Glenmark阿美替尼三代EGFR-TKI10.0 6^
表1：翰森制药2023-2025年主要对外授权交易汇总
这些BD交易的密集达成，不仅为公司带来了可观的首付款和里程碑付款收入，更重要的是验证了公司新药研发能力获得国际顶级药企的认可，为后续更多产品的海外授权铺平了道路。5. 竞争格局与行业地位5.1 中国创新药行业格局
中国创新药行业正处于高速发展的关键阶段。2025年，中国医疗健康 sector 股权融资达到创纪录的106亿美元，超过2022-2024年总和17^。在政策支持下，国产创新药正加速从"跟跑"向"并跑"乃至"领跑"转变。翰森制药在这一进程中扮演了重要角色，是中国传统药企成功转型的代表性企业。5.2 竞争对手对比分析
将翰森制药与国内主要创新药企进行横向对比，可以更清晰地定位其竞争优势。
图8：翰森制药与竞争对手关键指标对比（数据来源：公司年报、ifind，截至2025年5月）指标翰森制药恒瑞医药信达生物百济神州贝达药业市值（亿港元）2,2003,2007502,0002502025年PE34x55x45x35x40x研发费用率22.3%22.5%45.0%55.0%35.0%创新药收入占比82.2%55.0%95.0%98.0%90.0%2025年净利润（亿元）55.6~55盈利盈利~5核心优势肿瘤/代谢肿瘤全面PD-1/肿瘤全球化/血液瘤EGFR-TKI
表2：翰森制药与主要竞争对手关键指标对比
从上述对比可以看出，翰森制药的核心竞争优势主要体现在以下方面：一是盈利能力强，2025年净利润55.6亿元，在同行中处于领先水平，且PE估值仅为34倍，相对合理；二是创新转型成功，创新药收入占比从2020年的11%提升至2025年的82.2%，转型速度和深度在国内传统药企中罕见；三是BD能力突出，累计对外授权交易总额超90亿美元，展现了强大的国际化能力；四是代谢领域布局领先，在GLP-1/GIP双受体激动剂等热门赛道拥有差异化产品。5.3 细分赛道竞争分析
在三代EGFR-TKI赛道，阿美乐面临的主要竞争对手包括阿斯利康的奥希替尼（Tagrisso，进口原研）和贝达药业的贝福替尼。阿美乐的优势在于：获批适应症最多（5项）、医保覆盖充分、价格相对进口产品更具竞争力、联合化疗方案临床数据优异。2025年阿美乐实现海外上市和授权，进一步拓展了市场空间。
在GLP-1减重赛道，HS-20094面临的竞争格局更为激烈。国际市场上，礼来的替尔泊肽（Zepbound）和诺和诺德的司美格鲁肽（Wegovy）已占据先发优势。国内市场上，恒瑞医药、信达生物、华东医药等企业均在积极布局。HS-20094的差异化优势在于：与替尔泊肽同靶点（GLP-1/GIP双受体激动剂）但胃肠道耐受性更优6^，且通过对外授权合作借助Regeneron的全球化商业化能力，有望在国际市场获得可观份额。
在ADC赛道，公司的B7-H3 ADC和B7-H4 ADC属于全球同类靶点中进展较快的品种，与GSK的合作有助于加速海外临床开发和商业化进程。CDH17 ADC通过授权给罗氏，也验证了该靶点的成药性潜力。6. 风险因素分析6.1 政策与行业风险
中国医药行业正处于深度改革期，药品集中带量采购（集采）和国家医保谈判（NRDL）是影响行业格局的两大核心政策。翰森制药在早期仿制药集采中受到一定冲击，仿制药收入从2022年的43亿元降低至2024年的28亿元12^，但公司通过加速创新转型已逐步消化了集采影响。展望未来，公司核心创新药产品（如阿美乐、豪森昕福）均已纳入医保目录，后续面临的主要风险是医保续约时的价格调整压力。此外，创新药竞争加剧也可能导致市场价格下行。6.2 研发与临床风险
创新药研发具有高度的不确定性。公司在研的40余个候选创新药中，即使进入III期临床的品种仍存在研发失败的可能。特别是HS-20094（GLP-1/GIP）等处于热门赛道的产品，面临激烈的全球竞争，若临床数据不达预期或上市进度落后，可能错失最佳商业化窗口。此外，与跨国药企的授权合作中，里程碑付款的达成依赖于临床开发和监管审批的顺利推进，存在无法全额获取的风险。6.3 商业化与市场竞争风险
已上市产品的商业化表现可能不及预期。阿美乐作为公司收入支柱，若面临新一代EGFR-TKI的竞争或耐药性问题未得到有效解决，可能影响销售增长。在仿制药领域，随着专利到期和仿制药竞争加剧，存量产品面临持续的价格压力。此外，公司部分产品的市场推广曾涉及合规争议13^，医疗反腐的持续高压对公司的销售体系提出了更高的合规要求。6.4 国际化风险
公司的国际化战略主要通过产品授权（License-out）实现，虽然已达成多项重磅交易，但海外临床开发和商业化进程存在不确定性。合作伙伴（如GSK、Regeneron、Roche）可能因战略调整或临床数据不达预期而终止合作。此外，地缘政治因素、汇率波动等也可能影响海外收入的实现。6.5 股权集中度风险
控股股东持股超过64%，股权高度集中可能导致中小股东利益保护不足的风险。家族控股模式下，公司治理的透明度和决策的科学性也需要持续关注。7. 估值分析与投资建议7.1 历史估值回顾
翰森制药自2019年上市以来，估值经历了较大波动。上市初期估值一度高达60-70倍PE，2022-2023年因行业调整和仿制药集采影响，估值回落至20-30倍PE。2024年以来，随着创新药收入占比持续提升和BD交易密集达成，估值逐步修复至30-40倍PE区间。当前股价约22港元，对应2025年PE约34倍，在同行中处于中等偏低水平。
图4：翰森制药2023-2025年股价走势（数据来源：ifind，截至2025年5月）7.2 相对估值分析
与可比公司相比，翰森制药的PE估值低于恒瑞医药（55x）和信达生物（45x），与百济神州（35x）接近，高于传统仿制药企业。考虑到公司2025-2027年净利润预计保持15-20%的复合增速21^，以及创新管线的持续兑现和BD交易的价值释放，当前34倍的PE具有较好的安全边际。
券商分析师普遍给予公司正面评价。根据雅虎财经数据，当前有22位分析师覆盖翰森制药，其中5位给予"强烈买入"评级，16位给予"买入"评级，仅1位给予"持有"评级，无"卖出"评级15^。目标价均值约46.68港元，较当前股价有显著的上涨空间12^。7.3 绝对估值分析
华源证券采用DCF模型对公司进行估值，基于WACC 7.5%、永续增长率3.0%的假设，对应目标价33.90港元，首次覆盖给予"优于大市"评级12^。另有券商预测公司2026-2028年归母净利润分别为64.1亿、72.6亿、85.8亿元，对应PE分别为33x、29x、25x21^，估值水平将随盈利增长而逐步消化。7.4 投资建议
综合以上分析，我们认为翰森制药具备以下核心投资亮点：
第一，创新转型已进入收获期。 创新药收入占比从2020年的11%跃升至2025年的82.2%，标志着公司基本完成从仿到创的战略转变。7款创新药上市、11项适应症纳入医保，构成了稳健的收入基本盘。
第二，研发管线后劲十足。 40余个候选创新药、70余项临床试验正在推进，ADC、GLP-1/GIP、TYK2等多个重磅品种有望在未来3-5年内陆续获批上市，为持续增长注入新动能。
第三，国际化能力获得验证。 累计对外授权交易总额超90亿美元，合作伙伴涵盖GSK、默沙东、Regeneron、罗氏等全球顶级药企，不仅带来了可观的财务回报，更验证了公司的全球研发竞争力。
第四，财务状况极为稳健。 315亿元现金储备、极低的资产负债率、强劲的现金流生成能力，使公司具备穿越周期的抗风险能力和持续投入研发的财务实力。
第五，估值具备吸引力。 2025年PE约34倍，低于多数创新药企同行，考虑公司未来三年15-20%的盈利增速和管线价值，当前估值水平提供了较好的安全边际。
风险提示： 药品销售不及预期的风险、新药研发失败风险、行业竞争加剧风险、医保降价压力、国际化合作推进不及预期风险、汇率波动风险等。8. 总结与展望
翰森制药三十年发展历程，是中国制药产业从仿制走向创新的缩影。在创始人钟慧娟的领导下，公司从一家区域性仿制药企业成长为具有国际影响力的创新驱动型制药集团，不仅实现了经营业绩的跨越式增长，更重要的是走出了一条适合中国国情的药企转型之路。
展望未来，翰森制药正站在新的历史起点上。短期来看（2026-2027年），公司将继续受益于已上市创新药的持续放量和医保覆盖扩大，抗肿瘤领域的阿美乐、豪森昕福，代谢领域的孚来美、圣罗莱等产品有望保持稳健增长。中期来看（2028-2030年），ADC赛道的HS-20093、HS-20089，GLP-1/GIP赛道的HS-20094，TYK2赛道的HS-10374等重磅品种有望陆续获批上市，推动公司业绩迈上新台阶。长期来看，公司的全球化战略将从产品授权走向自主商业化，借助日益成熟的国际化BD能力和不断增强的研发实力，有望在全球创新药市场中占据更重要的位置。
对于投资者而言，翰森制药代表了一种兼顾成长性与确定性的投资选择。公司不像早期Biotech那样面临巨大的研发投入和盈利不确定性，也不像传统仿制药企那样面临增长乏力的困境，而是在成功完成创新转型的基础上，实现了持续盈利和稳健增长的双重目标。在当前中国创新药行业整体估值处于历史低位的背景下，翰森制药以其清晰的战略、扎实的管线和优异的财务表现，值得投资者重点关注。参考来源
[1^] 新浪财经，翰森制药2024年度业绩点评：创新驱动增长，管线蓄势待发，2025-03-24
[2^] 虎嗅，信达生物：稳了？，2025-03-11
[3^] 新浪财经，翰森制药2022创新药业绩再创新高，2023-03-28
[4^] 摩熵医药，翰森制药2026企业深度价值报告，2026-05-09
[5^] 中国经济网，翰森制药2025年业绩亮眼 强势增长彰显创新硬实力，2026-03-30
[6^] 经济观察网，创新药"优等生"：翰森制药业绩连年强劲增长，2026-03-31
[7^] 证券时报，首次成为中国女首富的钟慧娟，执掌的两千亿市值翰森制药是什么来头，2025-10-31
[8^] 投资界，新晋女首富诞生，翰森制药钟慧娟财富1400亿，2025-10-29
[9^] 中华网，翰森制药"斩获"罗氏15亿美元BD大单，2025-10-21
[10^] 新浪财经，翰森制药"斩获"罗氏15亿美元BD大单，2025-10-20
[11^] 智慧芽，翰森制药2025中期业绩：创新药收入占八成，2025-08-19
[12^] 海通国际，翰森制药首次覆盖优于大市研报，2025-06-15
[13^] 搜狐，医疗反腐持续高压，江苏豪森药业也出事了，2025-08-05
[14^] 翰森制药官网，2025 ASH 翰森制药创新药豪森昕福亮相，2025-12-19
[15^] 新浪财经，创新药收入占比83%！翰森制药创新转型做对了什么？，2025-08-22
[16^] 新浪财经，创新药收入占比83%！翰森制药创新转型做对了什么？，2025-08-22
[17^] 雅虎财经，中国医疗 sector 创纪录106亿美元融资，2025-12-27
[18^] 腾讯新闻，价值20亿美元！翰森制药授予默沙东口服减肥药全球独家许可权，2024-12-18
[19^] 界面新闻，药企积极布局新赛道，聚焦三大研发方向，2024-12-27
[20^] 腾讯新闻，中美新药20亿美元合作敲定，2024-12-20
[21^] 华源证券，翰森制药2025年报业绩点评：25年业绩亮眼，创新管线逐步进入兑现期，2026-04-20
[22^] 同花顺iNews，翰森制药2025财年全年净利润55.55亿人民币元，2026-03-29
[23^] 上海证券报，翰森制药2025年营收同比增长22.6% 创新产品占比达到82.2%，2026-03-29
[24^] 东方财富，翰森制药2025业绩：总收入超150亿元，2026-03-29
[25^] 腾讯新闻，ADC药物BD交易屡创高潮 翰森制药创新转型提速，2024-03-26
[26^] 21经济网，翰森创新药收入占比超八成 中国头部药企加速全球化创新突围，2025-08-21
[27^] 网易，2025年港股十大创新药企，2026-02-02
[28^] 富途，翰森制药财报-财务报告和业绩会，2025-09-23
[29^] 翰森制药官网，创新药收入占比83%媒体报道，2025-08-22
[30^] 网易，全球首款口服GLP-1减肥药获批上市，2025-12-23
[31^] 新浪财经，翰森20亿美元双协议：GLP-1和GLP-1-GIP双受体激动剂授权，2025-06-28
[32^] 翰森制药2024年度报告（PDF），2025-04-28
2026-05-11
·亚太易和
兽药原料资讯
新鲜资讯抢先了解
第二十三届中国畜牧业博览会 5月18-20日在成都举办
第十二届中国兽药展览会 6月18-19日在合肥举办
美德荣生物异麦芽酮糖项目高效转化，成本显著下降
欧盟对华柠檬酸发起第三次反倾销日落复审调查
东亚药业：富马酸伏诺拉生原料药获韩国原料药品注册证书
中牧股份2026 年第一季度营收15.09 亿元，同比增长19.86%
01
亨迪药业：原料药右旋布洛芬获巴西ANVISA GMP认证
5月7日，亨迪药业（301211）发布公告，公司于2025年11月24日至2025年11月28日接受了巴西国家卫生监督局（巴西ANVISA）的现场GMP认证，认证范围为化学原料药：右旋布洛芬。
公司近日收到巴西ANVISA核准签发的药品生产质量管理规范（GMP）认证证书，有效期限至2028年4月22日。
此次GMP认证的成功为公司右旋布洛芬原料药顺利进入巴西市场创造了条件，进一步拓展巴西市场和其他国际市场奠定了坚实基础，有利于提升公司的国际竞争力。
然而，医药产品的行业特点使得国际原料药业务易受国家政策、海外市场环境变化及供求关系等因素影响，具有一定的不确定性。
02
石家庄市古桥化工主要产品半胱胺盐酸盐产销两旺
赵县的石家庄古桥化工，半胱胺盐酸盐市场占有率超75%，一季度增长80%，假期不停产，产品远销多国，并拓展至新能源、新材料领域。
03
兄弟科技：全资子公司碘克沙醇原料药产品获得印度注册证书
5月7日，兄弟科技（002562）公告，全资子公司江西兄弟医药有限公司于近日收到印度中央药品标准管理局卫生和家庭福利部关于原料药（884143）产品的注册证书。产品名称为碘克沙醇，有效期自2026年4月29日至2029年4月28日。本次公司碘克沙醇原料药（884143）产品获得印度注册证书，标志着碘克沙醇原料药（884143）产品可以正式在印度市场进行销售，为公司碘造影剂原料药（884143）项目的产能释放及进一步拓展国际市场带来积极影响。
04
广东立国制药入选数据知识产权省级典型案例，实现“知产”变“资产”
近日，广东省市场监督管理局发布2025年度数据知识产权典型案例，我市广东立国制药有限公司的“头孢呋辛钠溶液不同批次工艺指数数据知识产权促进科技型企业盘活数据资产”案例成功入选，成为全省数据知识产权保护、运用的标杆示范，充分展现河源市在数据知识产权保护、运用及金融领域创新的先行探索与显著成效。
05
华北制药：自主研发+合作开发 碰撞创新“火花”元
近年来，华北制药坚持自主研发与对外合作协同发展，以科技创新驱动企业高质量发展。公司贯彻党的二十大关于“科技是第一生产力、人才是第一资源、创新是第一动力”的精神，聚焦市场需求，推动新产品研发与老产品焕新，如国家一类新药奥木替韦单抗注射液获批上市，以及注射用哌拉西林钠他唑巴坦钠销量大幅增长。通过建立研产销协同机制和激励制度，加快产品落地。同时，积极应用绿色新技术，如酶法工艺头孢氨苄有效降低污染物排放，微反应技术提升产品收率与安全性。依托微生物药物国家工程研究中心等国家级平台，华药加强对外合作，推动合成生物学等前沿技术应用，布局新型疫苗、抗体及宠物疫苗等领域。未来，华药将加快自主研发与成果转化，以科技支撑企业高质量发展和人民健康保障。
06
川宁生物股价持平 AI技术助力发酵工艺突破
川宁生物股价报12.29元，与前一交易日持平。盘中最高触及12.58元，最低下探12.20元，成交量为19.34万手，成交金额达2.39亿元。
川宁生物是新疆地区领先的生物技术企业，专注于抗生素中间体及合成生物产品的研发与生产。公司主要产品包括硫氰酸红霉素、头孢类中间体和青霉素类中间体，在生物发酵领域具有显著的技术优势。
公司近期与上海交通大学合作开发的AI工业自动控制系统取得显著成效，该系统使发酵罐平均产量提升3%-5%。2024年公司实现营业收入57.58亿元，同比增长19.38%；归母净利润14亿元，同比增长48.88%。公司研发投入达1.67亿元，已成功实现合成生物红没药醇量产，该产品纯度达99.9%，已进入欧莱雅等知名企业供应链。
川宁生物当日主力资金净流出2381万元，近五日累计净流出1040万元。融资方面，4月23日融资净偿还668.54万元，融资余额降至5.23亿元。
07
润辉生物：3年攻关 药物研发取得新突破
润辉生物技术（威海）有限公司近日获得国家药监局核准签发的依降钙素《化学原料药上市申请批准通知书》，成为国内首家获批该原料药的企业，打破了长期以来依赖进口的局面。依降钙素是一种由31个氨基酸组成的复杂环肽，用于骨质疏松治疗，较鲑鱼降钙素在稳定性和生物利用度方面更具优势。公司历时3年多、投入5000余万元，攻克了合成、环化及纯化等技术难题，最终实现国产突破。目前，润辉生物已成功研发20余种原料药，其中醋酸亮丙瑞林于2022年获GMP认证，为全国仅有的4家企业之一，填补山东省空白。公司被评为山东省“瞪羚”企业和“专精特新”中小企业，计划每年申报2-3个新品种，持续推动创新发展。
08
欧盟批准L-半胱氨酸、L-半胱氨酸盐酸盐-水合物和L-半胱氨酸盐酸盐作为所有动物的饲料添加剂
2026年5月8日，欧盟委员会发布法规（EU）2026/1012号条例，根据欧洲议会和理事会法规（EC） No 1831/2003，批准大肠杆菌DSM 34232生产的L-半胱氨酸、L-半胱氨酸盐酸盐-水合物和L-半胱氨酸盐酸盐作为所有动物的饲料添加剂。
根据附件中规定的条件，这种添加剂被授权作为动物添加剂的所属类别为“感官添加剂”，功能组别为“调味化合物”。授权结束日期为2036年5月28日。本条例自发布之日起第二十天生效。
09
新华制药神经退行性疾病领域管线布局再获突破
新华制药自主研发的盐酸苄丝肼原料药获国家药监局批准上市。该药是帕金森病治疗复方制剂“左旋多巴/苄丝肼”的核心组分，能降低左旋多巴的外周不良反应、提升疗效。其制剂为2025年国家医保甲类品种，2025年中国公立医疗机构相关制剂销售额约14亿元。此次获批补齐了新华制药在帕金森病治疗领域“左旋多巴+苄丝肼”双原料药自主供给的拼图，完善了神经退行性疾病产品线，并为供应链安全提供重要保障。
10
金河生物：2025年及2026年一季度，公司产品金霉素销售情况较好
金河生物在接受调研者提问时表示，2025年及2026年一季度，公司产品金霉素销售情况较好，国内市场由于金霉素应用场景增加，市场容量扩大，销量随之增加；美国市场销量稳中有升，同时积极开拓其他外销市场，销量有较大突破，六期项目成功投产为货源供应提供了保障。2025年公司结合下游市场需求等情况，对国内外市场金霉素产品的价格进行了上调，有力地保证了产品利润空间。
微信号丨ytyhyy
作者丨融媒体中心
总第4446期
100 项与 头孢氨苄 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨和关节感染 | 美国 | 2026-03-05 | |
| 急性细菌性鼻窦炎 | 澳大利亚 | 2004-02-24 | |
| 急性前列腺炎 | 澳大利亚 | 2004-02-24 | |
| 细菌性中耳炎 | 澳大利亚 | 2004-02-24 | |
| β-溶血性链球菌感染 | 澳大利亚 | 2004-02-24 | |
| 复杂的皮肤和软组织感染 | 澳大利亚 | 2004-02-24 | |
| 肺炎球菌感染 | 澳大利亚 | 2004-02-24 | |
| 细菌感染 | 中国 | 1981-01-01 | |
| 膀胱炎 | 日本 | 1978-08-01 | |
| 肺炎 | 日本 | 1978-08-01 | |
| 急性支气管炎 | 日本 | 1972-04-14 | |
| 复杂皮肤和皮肤结构感染 | 日本 | 1972-04-14 | |
| 泪囊炎 | 日本 | 1972-04-14 | |
| 睑腺炎 | 日本 | 1972-04-14 | |
| 颌骨炎症 | 日本 | 1972-04-14 | |
| 角膜炎 | 日本 | 1972-04-14 | |
| 淋巴结炎 | 日本 | 1972-04-14 | |
| 淋巴管炎 | 日本 | 1972-04-14 | |
| 乳腺炎 | 日本 | 1972-04-14 | |
| 上颌窦炎 | 日本 | 1972-04-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床4期 | 5 | Cefalexin+Levofloxacin+Amoxycillin+Oxacillin+Ceftriaxone+Dicloxacillin+Rifampicin+Ampicillin+Linezolid+Daptomycin+Vancomycin (Group I (Experimental)) | 醖繭壓顧廠構鏇襯顧獵(繭鹹蓋鏇製壓築膚鏇築) = 獵選鹽餘構齋鹹醖鬱糧 築鏇獵鏇糧壓築廠糧鑰 (製膚餘願鬱網醖衊鹹蓋, 顧範選選製淵構糧顧觸 ~ 糧襯顧醖淵淵顧願網膚) 更多 | - | 2026-05-05 | ||
(Group II (Control Group)) | 醖繭壓顧廠構鏇襯顧獵(繭鹹蓋鏇製壓築膚鏇築) = 齋夢築鏇衊鹽鏇觸壓廠 築鏇獵鏇糧壓築廠糧鑰 (製膚餘願鬱網醖衊鹹蓋, 窪衊觸廠艱觸醖鹽築鹹 ~ 鑰築壓鬱齋範願襯鬱糧) 更多 | ||||||
临床4期 | 94 | cefalexin+levofloxacin+Amoxicillin+doxycycline+delafloxacin+linezolid+amoxicillin-clavulanate+ciprofloxacin+cefpodoxime+cefadroxil (Group 1 (Experimental)) | 醖願糧鏇範鹹製鏇選繭 = 艱齋顧淵鏇蓋夢構齋鏇 蓋醖願築淵遞願醖廠壓 (範鹹顧顧糧積壓製鬱夢, 膚觸選艱網遞繭鬱齋顧 ~ 築艱餘膚鹽鹽夢獵齋網) 更多 | - | 2025-08-26 | ||
醖願糧鏇範鹹製鏇選繭 = 鬱構製範襯鏇顧憲繭憲 蓋醖願築淵遞願醖廠壓 (範鹹顧顧糧積壓製鬱夢, 窪壓獵壓膚夢膚齋餘膚 ~ 艱構願鹽艱簾願窪鑰鹹) 更多 | |||||||
临床1期 | 321 | Prophylactic Oral Cephalexin and Metronidazole | 簾膚襯衊積鑰鬱齋淵願(築壓鹹膚構齋淵糧積鬱) = 鬱壓糧簾憲鹹鹹壓選鏇 壓鹹醖鬱餘獵憲鑰鏇選 (簾構願窪糧壓製獵構築, 3.8 ~ 9.5) | 不佳 | 2025-05-22 | ||
Placebo | 簾膚襯衊積鑰鬱齋淵願(築壓鹹膚構齋淵糧積鬱) = 鬱蓋觸範鑰襯壓繭衊鹽 壓鹹醖鬱餘獵憲鑰鏇選 (簾構願窪糧壓製獵構築, 3.8 ~ 9.5) | ||||||
临床3期 | 98 | (Antibiotics for a 24 Hour Period) | 積顧構製鑰襯繭窪夢淵 = 鬱築簾鏇範壓廠獵膚鑰 遞窪觸糧繭蓋顧製餘鏇 (憲遞觸鏇窪構鑰選齋鏇, 夢醖願網鬱積遞鏇淵積 ~ 糧餘壓夢衊壓壓築壓選) 更多 | - | 2023-03-14 | ||
(Continued Antibiotics) | 積顧構製鑰襯繭窪夢淵 = 齋夢獵網襯憲製構鏇觸 遞窪觸糧繭蓋顧製餘鏇 (憲遞觸鏇窪構鑰選齋鏇, 簾鬱膚範衊鬱憲憲糧壓 ~ 夢構夢積願醖鑰廠繭願) 更多 | ||||||
临床4期 | 69 | High-dose cephalexin (1000 mg) | 選醖夢觸簾積淵網襯鹽(範壓襯鹽簾艱衊夢壓蓋) = 醖鹹鬱獵構衊範築觸醖 範繭蓋觸糧觸衊壓繭鬱 (構顧憲鑰衊觸築願艱夢, 43.1 ~ 59.8) | - | 2023-01-02 | ||
临床3期 | - | 醖餘鏇廠壓獵鑰製繭顧(製艱齋選遞網餘網夢餘) = 糧齋選選餘糧壓鏇餘遞 廠製醖齋齋齋鏇鹽膚衊 (鹽製願廠淵鹽繭網範醖 ) 更多 | 积极 | 2022-12-05 | |||
Cephalexin and placebo | 醖餘鏇廠壓獵鑰製繭顧(製艱齋選遞網餘網夢餘) = 鹹廠鬱簾壓鏇夢積餘簾 廠製醖齋齋齋鏇鹽膚衊 (鹽製願廠淵鹽繭網範醖 ) 更多 | ||||||
临床3期 | - | 製觸餘選鏇廠廠鬱餘顧(積積選顧簾窪願淵憲壓) = 壓願壓衊糧積淵製膚選 膚壓構構簾顧齋構夢餘 (簾鑰窪鑰夢膚膚醖餘餘 ) | - | 2021-11-01 | |||
Single dose of cefazolin | 製觸餘選鏇廠廠鬱餘顧(積積選顧簾窪願淵憲壓) = 觸簾觸觸鑰窪齋簾膚壓 膚壓構構簾顧齋構夢餘 (簾鑰窪鑰夢膚膚醖餘餘 ) | ||||||
临床2期 | 717 | (Standard Course Treatment) | 願積廠鹽鏇顧衊衊鑰鑰 = 壓繭築鹹遞衊窪願憲繭 積網齋窪鹽製構蓋獵鬱 (鹹淵憲鏇膚餘壓顧憲鑰, 鏇淵襯膚範艱構築鏇衊 ~ 膚構鹹醖壓窪齋齋壓鹽) 更多 | - | 2020-07-13 | ||
placebo (Short Course Treatment) | 願積廠鹽鏇顧衊衊鑰鑰 = 築憲簾夢網鑰窪獵網範 積網齋窪鹽製構蓋獵鬱 (鹹淵憲鏇膚餘壓顧憲鑰, 蓋鏇糧鬱廠醖糧顧夢憲 ~ 製齋構鑰淵蓋衊艱獵夢) 更多 | ||||||
N/A | 4 | (Keflex) | 觸簾淵壓積獵糧鬱餘憲(膚艱餘遞遞鹹窪醖蓋選) = 膚鑰糧糧構願醖壓鏇齋 蓋廠蓋網醖淵築築築繭 (選繭蓋構繭艱窪壓膚夢, 積鹽鬱醖蓋淵壓構衊鏇 ~ 顧築膚襯襯夢獵夢網窪) 更多 | - | 2019-04-16 | ||
placebo (Placebo) | 觸簾淵壓積獵糧鬱餘憲(膚艱餘遞遞鹹窪醖蓋選) = 夢鹹醖築艱鑰廠窪選艱 蓋廠蓋網醖淵築築築繭 (選繭蓋構繭艱窪壓膚夢, 選齋積鏇憲衊築網積築 ~ 願鏇襯構艱夢廠憲簾鏇) 更多 | ||||||
临床2期 | 206 | (IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin) | 網願廠鹽窪簾築鹽觸壓 = 遞觸鹹壓壓鏇廠夢範鹹 醖窪製鹽餘鬱鏇願鹽製 (淵網積繭憲糧積廠齋夢, 艱顧夢壓淵願艱築醖窪 ~ 鬱願遞繭壓夢鬱顧觸窪) 更多 | - | 2018-08-13 | ||
(Oral Cephalexin and Saline IV Plus Probenecid Placebo) | 網願廠鹽窪簾築鹽觸壓 = 鹹選夢壓夢餘憲鬱蓋壓 醖窪製鹽餘鬱鏇願鹽製 (淵網積繭憲糧積廠齋夢, 繭餘願齋淵鏇鑰蓋糧遞 ~ 齋醖餘築製構蓋夢壓膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用